Trading was light with 414K shares changing hands on Tuesday. Overall, volume was down 76.34% under the stocks normal daily volume.
Traders are more bearish on shares of the company of late if you put credence in the uptick in short interest. The firm saw a rise in short interest of 0.43% between September 29, 2017 and October 13, 2017. Short shares increased 3,885 over that timeframe. The days to cover decreased to 5.0 and the percentage of shorted shares was 0.04% on October 13.
Additionally, here are a few investment firms who have increased or decreased their stake in (QURE). As of the end of the quarter Ft Options LLC had disposed of 16,000 shares trimming its holdings by 80.0%. The value in dollars went from $15,000 to $1,000 a change of $14,000 for the reporting period. As of quarter end Ubs Group Ag had sold a total of 5,126 shares trimming its position 94.9%. The value of the total investment in uniQure N.V. – Ordinary Shares decreased from $31,000 to $2,000 a change of 93.5% quarter to quarter.
Cutler Group LP reduced its position by shedding 608 shares a decrease of 75.2% in the quarter. Cutler Group LP controls 200 shares worth $1,000. The total value of its holdings decreased 80.0%. As of quarter end P.a.w. Capital Corp had sold 20,000 shares trimming its stake by 16.0%. The value of the investment in QURE went from $774,000 to $1,008,000 increasing 30.2% since the last quarter.
The company is down from yesterday’s close of $14.90. Shares last traded at $14.90 which is quite a bit higher than $11.43, the 50 day moving average and much higher than the 200 day moving average of $7.81. The 50 day moving average was up $3.47 and the 200 day average moved up $7.09.
As of the last earnings report the EPS was $-2.82 and is expected to be $-3.00 for the current year with 25,560,000 shares now outstanding. Next quarter’s EPS is expected be $-0.70 and the next full year EPS is projected to be $-2.65.
uniQure N.V. (uniQure) is a gene therapy company. The Company is involved in developing single treatments with curative results for patients suffering from genetic and other severe diseases. The Company is advancing a focused pipeline of gene therapies that have been developed both internally and through partnerships. The Company?s product candidates include AMT-060 for Hemophilia B, AMT-130 for Huntington’s disease, S100A1 for congestive heart failure and Glybera for lipoprotein lipase deficiency (LPLD). uniQure has established clinical proof-of-concept in its lead indication, hemophilia B and has achieved pre-clinical, proof-of-concept in Huntington’s disease. The Company, through its collaboration with Bristol Myers-Squibb (BMS), is focused on building a portfolio of gene therapies led by the S100A1 program for congestive heart failure..